ArticleBioFactors (Oxford, England)
Dauriporphine Inhibits the Proliferation, Migration, Angiogenesis, and Glycolysis in Lung Cancer Cells by Repressing PGK1 Expression via CEBPA.
Article in BioFactors (Oxford, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many anti-cancer agents with therapeutic potential have been discovered in traditional Chinese medicine. Dauriporphine is an alkaloid extracted from Menispermum dauricum DC., demonstrating anti-cancer properties. However, the precise role of dauriporphine in the treatment of lung cancer and its underlying biological mechanism remains unclear. Dauriporphine addition resulted in reduced proliferation, migration, angiogenesis, and glycolysis in A549 and H1299 cells. Phosphoglycerate kinase 1 (PGK1) was identified as the candidate gene involved in glycolysis and dauriporphine after prediction using public datasets. Dauriporphine administration decreased PGK1 expression, whereas PGK1 overexpression markedly abolished the suppressive effects of dauriporphine. The CCAAT/enhancer binding protein A (CEBPA) was predicted to be the transcription factor of PGK1 using the online QIAGEN. The binding between CEBPA and PGK1 promoter was predicted and verified using Jaspar algorithm and Human TFDB, as well as chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, and cellular thermal shift assay (CETSA). CEBPA silencing could repress tumor cell malignant behaviors, which could be partially restored by PGK1 overexpression. Moreover, the upregulation of CEBPA diminished the anti-tumor efficacy of dauriporphine. Furthermore, dauriporphine treatment suppressed tumor growth by regulating the CEBPA/PGK1 pathway in nude mice. Overall, the study demonstrated that dauriporphine inhibited proliferation, migration, angiogenesis, and glycolysis in lung cancer cells via the CEBPA/PGK1 pathway, providing a potentially effective therapeutic strategy for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.